NCT06655545View on ClinicalTrials.gov

18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patients

CompletedOBSERVATIONAL

Enrollment

473

Participants

Timeline

Start Date

July 15, 2023

Primary Completion Date

October 15, 2024

Study Completion Date

February 1, 2025

Conditions

Breast Cancer

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER